Edition:
United States

Astellas Pharma Inc (4503.T)

4503.T on Tokyo Stock Exchange

1,958JPY
21 Sep 2018
Change (% chg)

¥-53 (-2.64%)
Prev Close
¥2,010
Open
¥2,010
Day's High
¥2,014
Day's Low
¥1,953
Volume
13,561,800
Avg. Vol
7,316,992
52-wk High
¥2,056
52-wk Low
¥1,380

Chart for

About

Astellas Pharma Inc. is a Japan-based company mainly engaged in the research, development, manufacture and sales of pharmaceutical products. The Company is involved in the manufacture and sale of pharmaceutical products in Japan, the United States, Europe, China, Korea, Taiwan and other markets through its subsidiaries. Its main... (more)

Overall

Beta: 0.48
Market Cap(Mil.): ¥3,980,435.00
Shares Outstanding(Mil.): 1,979.82
Dividend: 19.00
Yield (%): 1.79

Financials

  4503.T Industry Sector
P/E (TTM): 22.84 30.48 32.69
EPS (TTM): 88.04 -- --
ROI: 12.07 13.04 12.72
ROE: 13.62 14.99 14.85

Pfizer, Astellas revise two cancer drug trial protocols to speed up results

Drugmakers Pfizer Inc and Astellas Pharma Inc said on Wednesday they would change protocols for two late-stage trials testing prostate cancer drug Xtandi to speed up completion.

Aug 22 2018

Pfizer, Astellas revise two cancer drug trial protocols to speed up results

Aug 22 Drugmakers Pfizer Inc and Astellas Pharma Inc said on Wednesday they would change protocols for two late-stage trials testing prostate cancer drug Xtandi to speed up completion.

Aug 22 2018

BRIEF- Astellas Pharma signs exclusive licensing agreement with Aquinox Pharmaceuticals

* Says it signed an exclusive license agreement with Aquinox Pharmaceuticals, Inc for Japan and certain other countries in the Asia-Pacific region for Astellas to develop and commercialize rosiptor, Aquinox’s lead drug candidate, a first-in-class, once-daily oral treatment currently in Phase 3 clinical development for interstitial cystitis/bladder pain syndrome (IC/BPS) in North America and Europe

May 09 2018

BRIEF-Aquinox And Astellas Announce Exclusive Licensing Agreement For Rosiptor In Asia-Pacific Region Including Japan

* AQUINOX AND ASTELLAS ANNOUNCE EXCLUSIVE LICENSING AGREEMENT FOR ROSIPTOR IN ASIA-PACIFIC REGION INCLUDING JAPAN

May 09 2018

BRIEF-FDA Approves Supplemental New Drug Application For Myrbetriq For Treatment Of Overactive Bladder Symptoms

* FDA APPROVES SUPPLEMENTAL NEW DRUG APPLICATION FOR MYRBETRIQ® (MIRABEGRON) FOR USE IN COMBINATION WITH SOLIFENACIN SUCCINATE FOR THE TREATMENT OF OVERACTIVE BLADDER SYMPTOMS

May 07 2018

BRIEF-Astellas Pharma to retire treasury shares

* Says it will retire 89 million shares(4.3 percent stake) of its common stock on May 31

Apr 25 2018

BRIEF-Astellas Says To Cancel Treasury Stock Equivalent To 4.3 Percent Of Shares Outstanding

* ASTELLAS SAYS TO CANCEL TREASURY STOCK EQUIVALENT TO 4.3 PERCENT OF SHARES OUTSTANDING Further company coverage: (Reporting By Chris Gallagher)

Apr 25 2018

BRIEF-Astellas Pharma Submits NDA For Approval Of Gilteritinib

* ASTELLAS SUBMITS NEW DRUG APPLICATIONS FOR APPROVAL OF GILTERITINIB FOR THE TREATMENT OF FLT3MUT+ RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Apr 23 2018

BRIEF-Proteostasis Therapeutics - Co & Astellas Pharma Entered Into Amendment No. 6 To Collaboration & License Agreement

* PROTEOSTASIS THERAPEUTICS - ON APRIL 20, CO & ASTELLAS PHARMA ENTERED INTO AMENDMENT NO. 6 TO COLLABORATION & LICENSE AGREEMENT DATED NOVEMBER 4, 2014

Apr 23 2018

BRIEF-Astellas Announces Sale Of Certain Agensys Research Facilities To Kite, A Gilead Co

* ASTELLAS ANNOUNCES SALE OF CERTAIN AGENSYS RESEARCH FACILITIES TO KITE, A GILEAD COMPANY

Apr 18 2018

Earnings vs. Estimates